View Future GrowthAnGes 過去の業績過去 基準チェック /06AnGesの収益は年間平均-19.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 32.2%割合で 増加しています。主要情報-19.95%収益成長率-7.44%EPS成長率Biotechs 業界の成長17.04%収益成長率32.15%株主資本利益率-1,304.64%ネット・マージン-4,374.49%次回の業績アップデート09 May 2025最近の業績更新お知らせ • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026お知らせ • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025お知らせ • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025すべての更新を表示Recent updatesお知らせ • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026お知らせ • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.お知らせ • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026お知らせ • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.お知らせ • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025お知らせ • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025お知らせ • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025お知らせ • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024お知らせ • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024お知らせ • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024お知らせ • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.お知らせ • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.お知らせ • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.お知らせ • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024お知らせ • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.お知らせ • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.お知らせ • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.お知らせ • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023お知らせ • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023収支内訳AnGes の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:AMGX.F 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Dec 24643-28,1285,5743,78330 Sep 24521-9,7952,4304,26130 Jun 24448-6,1072,7415,25331 Mar 24249-6,3502,6405,56431 Dec 23152-7,4372,5116,17230 Sep 23124-9,3182,5857,31130 Jun 2387-12,1192,3827,54631 Mar 2368-14,6872,27710,31131 Dec 2267-14,7142,10410,99930 Sep 2265-11,9172,41110,82030 Jun 2272-13,6502,10212,43931 Mar 2268-13,2992,24810,63431 Dec 2164-13,6752,18910,78330 Sep 2155-12,9874,25910,40630 Jun 2146-9,7633,4917,65331 Mar 2145-6,6042,4395,58431 Dec 2039-4,2091,5713,79630 Sep 2031-4,1541,1642,50830 Jun 20170-3,6731,1852,18931 Mar 20255-3,4851,2682,84331 Dec 19326-3,7501,1842,21530 Sep 19656-3,5641,1602,87930 Jun 19605-3,8221,0593,26831 Mar 19612-3,6439222,53931 Dec 18610-2,9968832,53930 Sep 18387-2,6079021,66530 Jun 18373-2,6129551,61031 Mar 18356-2,7908831,72531 Dec 17365-3,7648612,60030 Sep 17513-4,3127973,17830 Jun 17514-4,2507273,17031 Mar 17514-5,0577704,07231 Dec 16514-4,7768004,18830 Sep 16366-4,9599444,14030 Jun 16359-4,9289054,23131 Mar 16432-4,4908693,76331 Dec 15430-4,1438823,53230 Sep 15948-3,2868083,21330 Jun 15975-3,4418093,23231 Mar 15908-2,8147622,73831 Dec 14909-2,3696872,33830 Sep 14381-2,5286732,01330 Jun 14351-1,7256451,31531 Mar 14448-1,4816571,156質の高い収益: AMGX.Fは現在利益が出ていません。利益率の向上: AMGX.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AMGX.Fは利益が出ておらず、過去 5 年間で損失は年間19.9%の割合で増加しています。成長の加速: AMGX.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AMGX.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: AMGX.Fは現在利益が出ていないため、自己資本利益率 ( -1304.64% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/04 00:01終値2024/12/05 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AnGes, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.Shinichiro MuraokaMorgan Stanley
お知らせ • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026
お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026
お知らせ • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
お知らせ • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025
お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025
お知らせ • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026
お知らせ • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
お知らせ • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.
お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026
お知らせ • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
お知らせ • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
お知らせ • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025
お知らせ • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.
お知らせ • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025
お知らせ • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024
お知らせ • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024
お知らせ • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024
お知らせ • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.
お知らせ • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.
お知らせ • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.
お知らせ • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024
お知らせ • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.
お知らせ • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.
お知らせ • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.
お知らせ • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023
お知らせ • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023